Self-transferable plasmid pIPilOO confers to Escherichia coli an unusually high level of resistance (1 to 2 mg/ni) to erythromycin by production of an erythromycin esterase. The effect of pIPllOO on the destiny of E. coli strains in the intestines of gnotobiotic mice was studied. In germfree mice, pIPllOO was efficiently transferred to a plasmid-free E. coli recipient. Intestinal counts of the donor, the recipient, and the transconjugants were greater than 8.5 log CFU/g of feces. When erythromycin was added to the diet of the mice, counts of the plasmid-bearing strains were only slightly lowered and partial inactivation of erythromycin was observed in the feces. Transfer of pIPllOO also occurred in human-flora-associated mice. In this model all the E. coli strains were subject to microbial antagonisms caused by the anaerobic components of the flora.
Microbial antagonisms have been observed in the intestinal tracts of humans and of experimental animals. They can be due to the action of a single strain against another strain belonging to the same genus (11) , to that of a defined mixture of strains against a strain of another genus (10) , or to that of complex endogenous microflora against pathogenic (29) or nonpathogenic (1) exogenous strains. These antagonisms can be affected to various extents by antimicrobial agents (1) .
The mechanisms proposed to account for the antagonisms exerted by the anaerobic intestinal flora of humans against members of the family Enterobacteriaceae include production of colicins or of volatile fatty acids, modification of bile acids, and competition for nutrients or for attachment sites on the mucosa (for a recent review see reference 15) . Less attention has been paid to the factors influencing susceptibility of the target cells to bacterial antagonisms. For example, members of the family Enterobacteriaceae harboring certain antibiotic resistance plasmids survive less well in the human intestinal tract than do their plasmid-free counterparts (13) . Transconjugants of an Escherichia coli strain have been shown to become established at a lower level than the susceptible parental strain in the digestive tracts of gnotobiotic mice in either the presence or the absence of human fecal bacteria (12) . However, this ecological disadvantage disappeared during antibiotic administration and even after the end of the drug intake (12) . Andremont et al. recently described E. coli BM2195, isolated from a human blood culture, which is resistant to high levels of erythromycin (MIC, 21 mg/ml) (A. Andremont, G. Gerbaud, and P. Courvalin, submitted for publication). This resistance phenotype is due to the presence of an erythromycin esterase which hydrolyzes the lactone ring of the antibiotic (4). The gene, designated ereA, encoding this new biochemical mech-anism of resistance in BM2195 is borne by a 61-kilobase (kb) plasmid, pIP1100, capable of self-transfer to other E. coli cells. Plasmid pIP1100 belongs to incompatibility group X and confers resistance to ampicillin, gentamicin, and streptomycin. The nucleotide sequence of the gene ereA has been determined (H. Ounissi and P. Courvalin, Gene, in press), and this new resistance gene was detected in various members of the family Enterobacteriaceae of human fecal origin by colony hybridization with a 716-base-pair intrageniS probe (M. Arthur, A. Andremont, and P. Courvalin, submitted for publication).
The destiny of strains harboring pIP1100 is of clinical importance, since intestinal strains inactivating antibiotics such as beta-lactams (24) or erythromycin (9) have been shown to interfere efficiently in vivo with antibiotic therapy. In the present study, we report the ecological disadvantage conferred by plasmid pIP1100 to strains of E. coli when they are associated with a human fecal flora in the intestines of gnotobiotic mice.
MATERIALS AND METHODS
E. coli strains. The sources and properties of the strains used in this study are listed in Table 1 . Plasmid pIP135-1 (Tra+ Inc7-M Tcr Hgr; 70.4 kb) (16) was introduced into E. coli C600(pIP1100) by conjugation (6) . E. coli BM21 organisms harboring plasmids ColEl::Tn3 (Tra-Mob' Apr; 11 kb) (26) and Tpll4 (Tra+ Incll Kmr; 62.5 kb) (14) were from our laboratory collection.
Determination of MICs. after they had been associated with a human fecal flora by intragastric and intrarectal inoculation (1) . To facilitate the enumeration of E. coli clones, the complex flora used was depleted of all members of the family Enterobacteriaceae by selective antimicrobial modulation of the intestinal tract of the human donor with erythromycin (1). Precise analysis of the resulting flora in mice showed that total bacterial counts and composition in anaerobes were not significantly altered by this procedure and that most of the resistance to colonization by exogenous members of the family Enterobacteriaceae was retained (1) . No antibiotic activity was detected in the feces of the recipient mice by a microbiological technique (7) . No coliform strain could be isolated from the feces of human-flora-associated (HFA) mice by repeatedly plating the pellets either directly or after 24 h of growth in brain heart infusion broth on Drigalski agar (Institut Pasteur Production, Paris, France). Mice were given drinking water (pH 3) ad libitum and fed with a locally prepared sterile diet supplemented when necessary with erythromycin (10 g/kg of diet) (1). GF and HFA mice were inoculated intragastrically (1 ml of a 108-CFU/ml broth culture) with one or two E. coli strains. In the latter case, the plasmid-free strain was inoculated 5 days before the plasmid-carrying derivative.
Bacterial Preparation of plasmid DNA. High-molecular-weight (23) and pBR322 and derivative pAT66 plasmid DNA (8) were prepared as described previously.
Agarose gel electrophoresis. Agarose gel electrophoresis was done as described previously (25) .
Hybridization. 32P-labeled pAT66 DNA was hybridized to bacterial colonies contained on nitrocellulose filters as described previously (19 
RESULTS
In control experiments, E. coli BM21, BM21(pIP1100), C600, and C600(pIP1100) could be individually established at high population levels in the intestines of GF monoassociated mice (Table 2) . By comparison, colonization was impaired by previous association of the mice with a human fecal flora. In mono-inoculated HFA mice, plasmid-free E. coli BM21 and C600 persisted at an intermediate level, whereas strain C600(pIP1100) was almost eliminated.
In experiments with di-inoculated animals, GF and HFA mice were inoculated at 5-day intervals with E. coli BM21 and E. coli C600(pIP1100), respectively. E. coli BM21 (pIP1100) transconjugants obtained in vivo could be isolated from the feces of both groups of animals ( Table 2 ). The presence of pIP1100 in the transconjugants was confirmed by agarose gel electrophoresis of crude bacterial lysates and by DNA-DNA hybridization ( Fig. 1 and 2 ). In GF di-inoculated mice, counts of E. coli BM21 and BM21(pIP1100) were high and similar to those observed in mono-inoculated GF animals (9.51 ± 0.15 and 9.00 ± 0.33 log CFU/g of feces, respectively [ Table 2 ]). Although the counts were high, a slight inhibition of strain C600(pIP1100) was observed in di-inoculated GF mice (8.61 ± 0.53 log CFU/g of feces). By contrast, in HFA di-inoculated mice, E. coli BM21 persisted at a level similar to that obtained in HFA mono-inoculated mice, but both donor strain C600(pIP1100) and transconjugants BM21(pIP1100) were either hardly or not detectable (2.55 ± 0.55 and 2.00 log CFU/g of feces, respectively).
Concentrations of erythromycin obtained in the feces of gnotobiotic mice under erythromycin treatment are presented in Fig. 3 . Antibiotic concentrations were significantly higher in HFA mice devoid of strains harboring plasmid pIP1100 than in mice with high fecal counts of strains carrying pIP1100 (P < 0.01). Concentrations of erythromycin were not significantly different in mice mono-associated with either E. coli BM21(pIP1100) or E. coli C600(pIP1100). During administration of erythromycin, E. coli BM21 was eliminated from both mono-and di-inoculated mice (Table  2) . Conversely, strains C600(pIP1100) and BM21(pIP1100), although at significantly lower levels, persisted in both groups of animals. Finally, in HFA mice no significant modification of the counts of the strains harboring pIP1100 was observed when erythromycin was added to the diet. DISCUSSION The physiological properties of strains harboring plasmid pIP1100 are of clinical importance, since dense intestinal populations of these strains partially inactive erythromycin in vivo (Fig. 3) . The concentrations of erythromycin obtained in the feces of gnotobiotic mice (Fig. 3) were similar to those reported for this model (1) or observed in humans under treatment with usual therapeutic regimens of erythromycin base (21) . This observation emphasizes the relevance of our results to the ecology of the intestinal tracts of humans.
Oral erythromycin has been shown to eliminate members of the family Enterobacteriaceae from the intestinal flora of humans (2) . This effect has been sustained for up to 3 weeks (28). This is due to the local concentrations of the antibiotic in the human intestinal tract, which are much higher than the MICs of erythromycin for endogenous members of the family Enterobacteriaceae (2) . Elimination of members of the family Enterobacteriaceae is associated with few modifications of the intestinal microbial antagonisms exerted by the anaerobic flora against exogenous microorganisms (1) . Erythromycin has also been used to prevent intestinal colonization by enteropathogenic members of the family Enterobacteriaceae in travelers (2) . Under these conditions, the presence of or the recolonization by members of the family Enterobacteriaceae highly resistant to erythromycin is a potential hazard. High-level resistance to erythromycin in E. coli and also, most probably, in other gram-negative bacteria can be secondary to mutations affecting ribosomal proteins (30) or to the acquisition of an erythromycinmodifying enzyme (Andremont et al., submitted for publication). In fact, an E. coli mutant of clinical origin highly resistant to erythromycin was previously shown to be able to colonize the intestinal tract of HFA mice before, during, and after erythromycin treatment (1) . The results of the present study clearly demonstrate that this is not the case for E. coli strains harboring plasmid pIP1100 ( Table 2 ). Transfer of pIP1100 was observed in the intestinal tract of di-inoculated gnotobiotic mice and was not hindered by the dense anaerobic flora of HFA mice. However, both donor and transconjugants were strongly inhibited in the intestines of HFA mice, whereas the plasmid-free recipient persisted at much higher concentrations. Since the specific inhibition of E. coli strains harboring pIP1100 was not observed in monoor di-inoculated GF mice in which no other bacteria were present, it is inferred that the presence of this plasmid confers on E. coli a specific susceptibility to the microbial antagonisms exerted by the human fecal flora harbored by the HFA mice. By contrast with results reported for other resistance plasmids (12) , the ecological disadvantage mediated by pIP1100 in HFA mice did not disappear under antibiotic treatment. Under these conditions, no increase in the population levels of the strains harboring pIP1100 was observed. The presence of E. coli BM21(pIP1100) and C600(pIP1100) in counts over 6.00 log CFU/g of feces in GF mice inoculated with these two strains and treated with erythromycin indicates that administration of the antibiotic does not account for the persistence of this drastic inhibition. Erythromycin treatment had some effect on the level of colonization by strains harboring pIP1100 when the pretreatment counts were high. This effect is probably related to the fact that the MICs of erythromycin for E. coli strains bearing pIP1100 (1,024 to 2,048 mg/liter; Table 1 ) and the concentrations of the drug recovered from the feces of the animals (1.040 to 2.220 mg/g; Fig. 3 ) are within the same range. This effect is not observed with more resistant stains (MIC, >4,096 mg/liter) (1). This finding is consistent with the low prevalence of human intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin (A. Andremont, H. Sancho-Garnier, and C. Tancrede, submitted for publication), despite the extensive use of this antibiotic over the past 20 years. This observation favors further use of oral erythromycin for selective antimicrobial modulation of the intestinal tract.
